Cilnidipine + Metoprolol ER Tablets

Project Image
Thumb Image

Therapeutic Indication

Essential hypertension
Cardiovascular risk reduction
Adjunct therapy in ischemic heart disease
+91 85919 78885

Cilnidipine + Metoprolol ER

Tablet

This fixed-dose combination provides dual antihypertensive action. Cilnidipine, a calcium channel blocker, reduces vascular resistance, while Metoprolol ER, a beta-blocker, lowers heart rate and myocardial oxygen demand. Together, they provide effective blood pressure control and cardiovascular protection.

Speciality Cardiology | Hypertension Management | Internal Medicine
Tags Hypertension | Calcium Channel Blocker | Beta-blocker | Cardioprotection | Combination Therapy
Strength
  • Cilnidipine 10 mg / 20 mg
  • Metoprolol Succinate ER 47.5 mg
Packing Size
  • 10 Tablets

Check all Tablet Range

Click to know More

Mechanism

Cilnidipine: Dual L/N-type calcium channel blocker → reduces vascular resistance and sympathetic nerve activity.
Metoprolol ER: Selective β1-blocker → decreases heart rate, cardiac output, and myocardial oxygen demand.

Pharmacokinetics

  • Cilnidipine Absorption: Oral bioavailability ~40%; peak plasma levels in 2 hrs.
  • Metoprolol ER Absorption: Extended release formulation ensures steady plasma levels.
  • Distribution: Both widely distributed; Metoprolol ~12% protein bound.
  • Metabolism: Cilnidipine metabolized hepatically; Metoprolol via CYP2D6.
  • Excretion: Both primarily renal excretion.
  • Half-life: Cilnidipine ~2–5 hrs; Metoprolol ER ~6–9 hrs.

Side Effects

  • Dizziness
  • Fatigue
  • Bradycardia (Metoprolol)
  • Peripheral edema (Cilnidipine)
  • Rare: Hypotension, AV block

Contraindication

  • Severe bradycardia or AV block
  • Cardiogenic shock
  • Hypersensitivity to either component

Interaction

  • Other antihypertensives may potentiate hypotension
  • NSAIDs may reduce antihypertensive effect
  • Beta-blockers with verapamil/diltiazem ↑ risk of bradycardia

Warning and Precautions

  • Monitor blood pressure and heart rate regularly
  • Use cautiously in patients with asthma or COPD (Metoprolol)
  • Gradual withdrawal recommended to avoid rebound hypertension

Disclaimer

All product details on this website are for reference and informational purposes only and are not directed at patients or consumers.
As a contract manufacturer, DM Pharma Pvt Ltd is not responsible for the marketing or end use of these products and disclaims all liability arising from reliance on this information.
Please consult a healthcare professional before using any medicinal product.